News about Clinical Trials

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Trial of AT-587 for Hepatitis E Treatment

Atea Pharmaceuticals has initiated a first-in-human Phase 1 clinical trial evaluating AT-587, an investigational oral antiviral candidate for hepatitis E virus (HEV) infection. The study will assess the drug's safety and pharmacokinetics, supporting the development of a potential new treatment for chronic HEV, particularly in immunocompromised patients.

Clinical Trials | 17/07/2026 | By News Bureau

Ascletis Selects Oral ASC30-ASC48 Fixed-Dose Combination for Clinical Development in Obesity

Ascletis Pharma has selected its ASC30-ASC48 fixed-dose combination for clinical development as a once-daily oral therapy for obesity. The dual-target GLP-1R/GIPR candidate demonstrated encouraging preclinical efficacy, with an IND submission to the US FDA planned for Q4 2026.

Clinical Trials | 17/07/2026 | By News Bureau

GSK's Jemperli Shows Durable Complete Responses in Rectal CancerGSK's Jemperli (dostarlimab) achieved durable complete responses in dMMR/MSI-H locally adva

GSK's Jemperli (dostarlimab) achieved durable complete responses in dMMR/MSI-H locally advanced rectal cancer, with potential to avoid chemotherapy, radiation, and surgery in some patients.

Clinical Trials | 14/07/2026 | By News Bureau

Novo Nordisk Reports Positive Long-Term Phase 3 Data for Investigational Hemophilia A Therapy Denecimig

FRONTIER4 extension study demonstrates sustained safety, low bleeding rates and flexible dosing across children, adolescents and adults, while new data on concizumab highlights reduced bleeding episodes in pediatric patients with hemophilia.

Clinical Trials | 13/07/2026 | By News Bureau

AstraZeneca, Ionis' Wainua Misses Phase 3 Primary Endpoint in ATTR-CM Trial

AstraZeneca and Ionis reported that Wainua (eplontersen) missed the primary endpoint in the phase 3 CARDIO-TTRansform trial for ATTR-CM, while maintaining a consistent safety profile.

Clinical Trials | 10/07/2026 | By News Bureau

TG Therapeutics Launches Phase 2 Trial of BRIUMVI for Schizophrenia

TG Therapeutics has initiated a Phase 2 trial of BRIUMVI in treatment-resistant schizophrenia, evaluating B-cell depletion as a potential therapy for patients with immune dysfunction.

Clinical Trials | 07/07/2026 | By News Bureau |  100

Opus Genetics Aligns with US FDA on Phase 3 OPGx-LCA5 Trial

Opus Genetics has aligned with the US Food and Drug Administration (FDA) on the Phase 3 trial design for OPGx-LCA5 in inherited retinal disease, with phase 3 dosing expected in Q4 2026 and a potential Biologics License Application (BLA) submission based on 6-month efficacy data.

Clinical Trials | 07/07/2026 | By News Bureau

AtaiBeckley Completes Patient Dosing in Phase 2b Trial of VLS-01 for Treatment-Resistant Depression

AtaiBeckley has completed dosing the final patient in its Phase 2b Elumina trial evaluating VLS-01 for treatment-resistant depression. The company expects topline results in the fourth quarter of 2026 and plans to expand the therapy into major depressive disorder and generalized anxiety disorder, subject to positive clinical outcomes.

Clinical Trials | 07/07/2026 | By News Bureau

Ionis Completes Enrollment in Phase 3 REVEAL Study for Angelman Syndrome

Ionis has completed enrollment in the pivotal Phase 3 REVEAL study of obudanersen for Angelman syndrome, with topline clinical trial results expected in the second half of 2027.

Clinical Trials | 06/07/2026 | By Akanki |  164

Immunomic Therapeutics Doses First Patient in Phase 1 Trial of Japanese Cedar Allergy Vaccine

Immunomic Therapeutics has initiated Phase 1 clinical testing of ITI-9001 after dosing the first participant in Japan, advancing the development of a next-generation therapeutic vaccine for Japanese cedar pollen allergy.

Clinical Trials | 06/07/2026 | By News Bureau